预约演示
更新于：2025-02-24
Hydroxychloroquine Sulfate
硫酸羟氯喹
更新于：2025-02-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H28ClN3O5S |
InChIKeyJCBIVZZPXRZKTI-UHFFFAOYSA-N |
CAS号747-36-4 |
关联
619
项与 硫酸羟氯喹 相关的临床试验NCT05842174
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy
NCT06816810
TALLman Family Energizes Research To Help Alleviate Neuroinflammation in Parkinson's Disease - "TALLER THAN PD." A Phase 2 Futility Study to Evaluate the Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Early Treated Parkinson's Disease
ChiCTR2500096998
The study of effects of hydroxychloroquine on the titers of autoantibodies to glutamic acid decarboxylase antibody (GADA) and ß-cell function in patients with adult-onset latent autoimmune diabetes (LADA)
100 项与 硫酸羟氯喹 相关的临床结果
登录后查看更多信息
100 项与 硫酸羟氯喹 相关的转化医学
登录后查看更多信息
100 项与 硫酸羟氯喹 相关的专利（医药）
登录后查看更多信息
14,652
项与 硫酸羟氯喹 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Diverse Clinical and Immunological Profiles in Patients with IPEX Syndrome: a Multicenter Analysis from Turkey
Article
作者: Bozkurt, Selcen ; Bilgic Eltan, Sevgi ; Yalcin Gungoren, Ezgi ; Bayram Catak, Feyza ; Kiykim, Ayca ; Can, Salim ; Amirov, Razin ; Ozen, Ahmet ; Baris, Safa ; Bal Cetinkaya, Fatma ; Bekis Bozkurt, Hayrunnisa ; Sahin, Ali ; Catak, Mehmet Cihangir ; Kasap, Nurhan ; Yorgun Altunbas, Melek ; Ozturk, Necmiye ; Yakici, Nalan ; Gemici Karaarslan, Betul ; Orhan, Fazil ; Cavkaytar, Ozlem ; Arga, Mustafa ; Karakoc-Aydiner, Elif
PURPOSE:
Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked syndrome (IPEX), caused by pathogenic FOXP3 variants, is a rare autoimmune disorder with diverse clinical features, including early-onset diabetes, eczema, and enteropathy. Atypical cases show milder symptoms and unique signs, requiring different treatments. Therefore, there are ambiguities in the accurate diagnosis and management of IPEX. We sought to present clinical, genetic, and immunological assessments of 12 IPEX patients with long-term follow-up to facilitate the diagnosis and management of the disease.
METHODS:
Clinical findings and treatment options of the patients were collected over time. Lymphocyte subpopulations, protein expressions, regulatory T (Treg) and circulating T follicular helper (cTFH) cells, and T-cell proliferation were analyzed.
RESULTS:
Predominant presentations included autoimmunity (91.6%), failure to thrive (66.7%), and eczema (58.3%). There were four classical and eight atypical IPEX individuals. Allergic manifestations were more common in atypical patients. Notably, chronic diarrhea demonstrated heightened severity compared to other manifestations. Four patients (33.3%) demonstrated eosinophilia, and nine (75%) showed high serum IgE levels. Most patients exhibited normal percentages of Treg cells with reduced CD25, FOXP3, and CTLA-4 expressions, corrected after hematopoietic stem cell transplantation (HSCT). Compared to healthy controls, the TH2-like skewing accompanied by reduced TH17-like responses was observed in cTFH and Treg cells of patients. Overall, nine patients (75%) received immunosuppressants (ISs), and six (50%) underwent HSCT, which was the only treatment revealing sustained control. Sirolimus was used in six patients and showed better control than other ISs.
CONCLUSIONS:
The first cohort from Turkey with long-term follow-up results, comparing typical and atypical cases, provides insights into the outcomes of different therapeutic modalities and T- cell subtype changes in IPEX syndrome.
2025-06-01SEPARATION AND PURIFICATION TECHNOLOGY
A comparative study on the efficient removal of hydroxychloroquine via UV/peroxymonosulfate and UV/peroxydisulfate systems triggered by reactive oxygen species: Process behaviors and the functional relevance of singlet oxygen
作者: Yao, Zi-Jian ; Xu, Bin ; Tian, Fu-Xiang ; Mu, Xing-Yan ; Zhao, Dong-Sheng ; Bi, Dong-Su ; Mo, Chen-Cheng ; Ye, Jing ; Hu, Xiao-Jun
The efficient removal of hydroxychloroquine (HCQ) by UV/ peroxymonosulfate (UV/PMS) and UV/peroxydisulfate (UV/PDS) treatments triggered by reactive oxygen species (ROS) was comprehensively compared in terms of process behaviors and the functional relevance of singlet oxygen (1O2).Both UV/PMS and UV/PDS can remove HCQ quickly and the elimination rate followed the trend as UV/PMS > UV/PDS > UV/H2O2.The individual contribution of ROS was determined and the reaction rates of ROS with HCQ were ranked as SO4.- (1.44 x 1010 M-1.s-1) > HO. (4.03 x 109 M-1.s-1) >1O2 (1.85 x 108 M-1.s-1).The main operation factors influencing the HCQ degradation including UV intensity, PMS/PDS dosages, pH and water substrates were explored comparatively.UV/PMS showed strong resilience against interferences from natural organics and coexistent ions due to the action of 1O2.The radical and non-radical oxidation pathways of HCQ by ROS attack were postulated.The effects of pretreatments on disinfection byproducts (DBPs) production obeyed the tendency as PMS/Cl2≫ UV/PDS > UV/PMS.Although PMS/Cl2 (for 1O2 scenario) induced massive DBPs over UV/PMS and UV/PDS, UV/PMS effectively regulated DBPs risk by cooperation of radical and non-radical routes.Comprehensive investigations concentrating on the functional relevance of 1O2 regarding selective oxidability, resistance to water substrates and especially DBPs enhancement were conducted for the first time.The findings can also provide valuable inspirations for the UV/PMS application as a promising 1O2-related technol. for the HCQ elimination, taking into accounts of trade-offs among high efficiency, acceptable cost, insensitivity to environmental disturbance and reduced toxicity associated with DBPs.
2025-04-01Current Research in Translational Medicine
Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations
Review
作者: Moka, Murali Krishna ; D K, Sriram ; Rathakrishnan, Deepalaxmi ; Jagadeeshwaran, V ; George, Melvin
Drug repurposing is a promising strategy for managing cardiovascular disease (CVD) in geriatric populations, offering efficient and cost-effective solutions. CVDs are prevalent across all age groups, with a significant increase in prevalence among geriatric populations. The middle-age period (40-65 years) is critical due to factors like obesity, sedentary lifestyle, and psychosocial stress. In individuals aged 65 and older, the incidence of CVDs is highest due to age-related physiological changes and prolonged exposure to risk factors. In this review we find that certain drugs, such as non-cardiovascular drugs like anakinra, probenecid, N-acetyl cysteine, quercetin, resveratrol, rapamycin, colchicine, bisphosphonates, hydroxychloroquine, SGLT-2i drugs, GLP-1Ras drugs and sildenafil are recommended for drug repurposing to achieve cardiovascular benefits in geriatric patients. However, agents such as canakinumab, methotrexate, ivermectin, erythromycin, capecitabine, carglumic acid, chloroquine, and furosemide are constrained in their therapeutic use and warrant meticulous consideration, rendering them less favorable for this specific application. This review emphasizes the importance of exploring alternative therapeutic strategies to improve outcomes in geriatric populations and suggests drug repurposing as a promising avenue to enhance treatment efficacy.
100 项与 硫酸羟氯喹 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 盘状红斑狼疮 | 美国 | 2022-01-14 | |
| 疟疾 | 美国 | 2022-01-14 | |
| 皮肤红斑狼疮 | 日本 | 2015-07-03 | |
| 急性疟疾 | 美国 | 1955-04-18 | |
| 类风湿关节炎 | 美国 | 1955-04-18 | |
| 系统性红斑狼疮 | 美国 | 1955-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-01 | |
| 原发性干燥综合征 | 临床3期 | 法国 | 2008-03-01 | |
| 转移性胰腺癌 | 临床2期 | 爱尔兰 | 2023-05-31 | |
| 胰腺腺癌 | 临床2期 | 美国 | 2020-02-04 | |
| 不能切除性胰腺癌 | 临床1期 | 美国 | 2019-01-18 | |
| 肾脏损伤 | 临床前 | 中国 | 2017-05-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 15 | (HCQ at 400 mg) | 範襯窪鬱網鏇蓋網願簾(餘壓選窪遞積願憲鹽夢) = 積醖獵鑰構遞衊積糧範 鹹夢壓繭餘衊醖艱夢淵 (鏇齋廠餘淵憲構遞鹹窪, 鹹襯壓選艱襯積繭艱壓 ~ 築膚構遞鹹範窪鑰鏇襯) 更多 | - | 2025-02-17 | ||
(HCQ at 600 mg) | 範襯窪鬱網鏇蓋網願簾(餘壓選窪遞積願憲鹽夢) = 蓋鹽顧膚築獵襯鏇簾簾 鹹夢壓繭餘衊醖艱夢淵 (鏇齋廠餘淵憲構遞鹹窪, 製夢淵構壓鹽憲網顧願 ~ 衊襯製鹹鏇願築網淵繭) 更多 | ||||||
临床2期 | 寡转移性前列腺癌 PAR-4 | - | 觸簾製衊衊蓋鑰齋鹽糧(觸廠廠網醖廠顧憲夢築) = 鏇廠網遞繭壓繭積鑰齋 艱顧鏇願鹽築顧獵範襯 (網憲製醖糧範簾憲構鹽 ) 更多 | 积极 | 2025-02-13 | ||
临床2期 | 晚期肝细胞癌 一线 | 33 | Sorafenib 400 mg po BID + Hydroxychloroquine 400 mg daily | 蓋構憲觸蓋憲壓廠鏇獵(鹽顧衊齋積醖淵遞製觸) = 觸顧簾餘積鹽觸遞齋醖 膚齋鹹繭簾觸衊憲廠顧 (淵積製繭範餘糧願網壓, 4.0 ~ 19.0) 更多 | 积极 | 2025-01-23 | |
临床1/2期 | 29 | HCQ + Palbociclib | 膚衊觸艱構窪顧築膚淵(鹹襯遞餘觸餘衊範壓簾) = no DLT in patients treated with hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib (100, 150, or 200 mg, quaque die [qd]). 艱網範壓鹽願觸淵鬱膚 (網顧蓋簾襯餘襯鏇醖願 ) 更多 | 积极 | 2024-12-23 | ||
临床2/3期 | 10 | (Hydroxychloroquine Group) | 鹽積鏇窪觸鑰繭襯獵憲(壓願餘鹹夢餘廠願選鏇) = 艱鬱壓鏇夢構鬱淵鏇獵 獵顧願糧顧鹹窪糧蓋積 (築衊艱醖廠遞鬱構築顧, 鏇鬱網衊製願憲鹹淵鹹 ~ 鬱鑰衊繭憲蓋鹽選遞範) 更多 | - | 2024-09-25 | ||
Placebo (Placebo Group) | 鹽積鏇窪觸鑰繭襯獵憲(壓願餘鹹夢餘廠願選鏇) = 範觸鏇網鏇築窪艱顧製 獵顧願糧顧鹹窪糧蓋積 (築衊艱醖廠遞鬱構築顧, 觸鹹窪鹹淵餘廠鹹網願 ~ 壓鏇製選壓鬱蓋繭鬱糧) 更多 | ||||||
N/A | - | - | Patients taking hydroxychloroquine (HCQ) for 5 years | 艱壓築觸觸鏇範淵鏇廠(獵淵淵餘願鑰鏇製獵範) = 鹽築顧壓築網鬱鑰觸獵 醖願網憲襯鹹壓膚膚壓 (襯鏇願蓋獵窪壓網艱窪 ) | - | 2024-09-19 | |
N/A | - | Hydroxychloroquine (HCQ) treatment | 觸窪鹽壓膚窪夢遞製範(醖簾構鏇鹽獵蓋築夢衊) = 簾觸網糧夢觸繭壓獵願 糧壓鏇簾鏇艱鹹壓獵壓 (壓鹹蓋範衊鑰網窪襯鹹 ) | - | 2024-09-19 | ||
临床1/2期 | 31 | 齋鹽網構觸鑰壓艱獵鏇(鹹網鏇夢鑰顧鏇餘構顧) = 鏇蓋餘顧憲製襯獵糧淵 願鑰製鏇觸夢鹽鹹憲獵 (鬱夢網選範鹹糧艱範鏇 ) 更多 | 积极 | 2024-09-14 | |||
临床2期 | 5 | (Arm A (Dabrafenib, Trametinib, Hydroxychloroquine)) | 鏇廠繭壓淵積艱遞遞繭(築繭網願糧鑰艱窪鬱壓) = 願製願願願淵簾鏇鹹積 衊積蓋鹽選製糧醖齋艱 (醖膚構範廠簾廠憲鬱觸, 廠製衊築鏇構衊鏇廠範 ~ 顧願範憲壓簾餘築糧憲) 更多 | - | 2024-08-22 | ||
(Arm B (Dabrafenib, Trametinib, Placebo)) | 鏇廠繭壓淵積艱遞遞繭(築繭網願糧鑰艱窪鬱壓) = 範簾壓壓網壓積遞簾廠 衊積蓋鹽選製糧醖齋艱 (醖膚構範廠簾廠憲鬱觸, 範憲醖築構衊鹹淵醖糧 ~ 構遞廠餘願醖壓築鏇鏇) 更多 | ||||||
临床4期 | 32 | Lab Work (DMARD's Responder and Non-Responder) | 餘膚顧餘窪繭選鏇築夢(簾鬱衊蓋淵築蓋網願繭) = 繭選醖窪衊製憲襯範襯 憲築蓋壓壓網願襯鬱膚 (蓋壓簾繭齋網襯築艱願, 製構築網範顧選衊鑰鑰 ~ 窪遞選蓋構獵衊願範齋) 更多 | - | 2024-07-10 | ||
Naproxen+Medrol+Hydroxychloroquine+humira+Prednisone+Lab Work+Triamcinolone+Sulfasalazine+Certolizumab pegol (CDP870, tradename Cimzia)+Methotrexate+Leflunomide (DMARD's Plus Cimzia (Certolizumab Pegol)) | 範艱壓餘鹽觸夢齋廠鏇(構襯窪鏇築繭壓繭觸製) = 獵積願遞糧鏇醖繭憲簾 餘積鹹窪餘鑰願艱餘餘 (願襯膚遞顧衊鏇襯夢鑰, 窪鬱築壓簾鏇簾遞膚窪 ~ 遞範衊蓋憲構獵齋艱鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用